SAB Biotherapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of SABS for the last quarter is 305.01 k USD, and it's 75.93% lower compared to the previous quarter. The net income of Q4 23 is -22.86 M USD.